Search

Your search keyword '"Blombery P."' showing total 534 results

Search Constraints

Start Over You searched for: Author "Blombery P." Remove constraint Author: "Blombery P."
534 results on '"Blombery P."'

Search Results

5. Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

6. CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma.

11. Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

14. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

16. Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition

17. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

18. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

21. Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).

22. Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

23. Observations from a national sample exchange program for molecular haematology testing

26. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.

27. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

28. Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

29. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

30. Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION

32. Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry

33. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

35. Management of thrombotic thrombocytopenic purpura: current perspectives

38. VEXAS syndrome: A dermatological perspective

39. Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review

40. Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics

41. Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors

42. ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemia

43. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL

44. JAFFAL: detecting fusion genes with long-read transcriptome sequencing

45. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

47. Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre

48. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

49. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41

Catalog

Books, media, physical & digital resources